Methods of treating ischemia
AssigneeFate Therapeutics, Inc.
InventorsDan Shoemaker, Pratik S. Multani, John D. Mendlein, David Robbins
Life of this patent
Estimating the term…
Abstract
The invention provides compositions comprising stem and/or progenitor cells that have been treated to enhance the therapeutic properties of the cells for treating ischemia. In particular, the present invention relates to the use of stem and/or progenitor cells having enhanced therapeutic properties to treat an ischemic tissue, a tissue damaged by ischemia, or at least one symptom associated with an ischemic tissue or a tissue damaged by ischemia.
Claims20
-74. (canceled)
A method of treating a subject having an ischemic tissue or a tissue damaged by ischemia comprising:
- administering a therapeutically effective amount of a composition comprising stem or progenitor cells treated ex vivo with a prostaglandin pathway agonist and a glucocorticoid, under conditions sufficient to increase CXCR4 gene expression at least two fold in the treated stem or progenitor cells compared to non-treated stem or progenitor cells.
A method of improving vascularization to a damaged tissue:
- administering a therapeutically effective amount of a composition comprising stem or progenitor cells treated ex vivo with a prostaglandin pathway agonist and a glucocorticoid to a subject with damaged tissue.
A cell graft or biocompatible scaffold having increased recruitment of endogenous cells to tissue damage in vivo comprising:
- (a) hematopoietic stem or progenitor cells contacted ex vivo with a prostaglandin pathway agonist and, optionally, a glucocorticoid;
- and
- (b) a biocompatible natural and/or synthetic structure.
Dependencies are inferred from the claim text.